Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction

Biomarker Research

Review

Yu Ping¹  Ruixia Song²  Fengsen Liu³  Yi Zhang⁴  Liping Wang⁵ 

[1] Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou University, Zhengzhou, Henan, China;Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou University, Zhengzhou, Henan, China;School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China;Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou University, Zhengzhou, Henan, China;School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China;State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou, Henan, China;Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;

关键词: Cancer;    Immune checkpoint inhibitors;    Biomarkers;    Treatment outcome;    Prognosis;   

DOI  :  10.1186/s40364-023-00498-1

 received in 2023-02-01, accepted in 2023-05-07,  发布年份 2023

来源: Springer

【 摘 要 】

Immune checkpoint inhibitors (ICIs) have dramatically enhanced the treatment outcomes for diverse malignancies. Yet, only 15–60% of patients respond significantly. Therefore, accurate responder identification and timely ICI administration are critical issues in tumor ICI therapy. Recent rapid developments at the intersection of oncology, immunology, biology, and computer science have provided an abundance of predictive biomarkers for ICI efficacy. These biomarkers can be invasive or non-invasive, depending on the specific sample collection method. Compared with invasive markers, a host of non-invasive markers have been confirmed to have superior availability and accuracy in ICI efficacy prediction. Considering the outstanding advantages of dynamic monitoring of the immunotherapy response and the potential for widespread clinical application, we review the recent research in this field with the aim of contributing to the identification of patients who may derive the greatest benefit from ICI therapy.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2023_37_Article_IEq136.gif

41116_2023_37_Article_IEq130.gif

41116_2023_37_Article_IEq125.gif

41116_2023_37_Article_IEq121.gif